申请人:E.R. SQUIBB & SONS, INC.
公开号:EP0536713A1
公开(公告)日:1993-04-14
Thromboxane receptor antagonist activity is exhibited by compounds of the formula
wherein:
V is -(CH₂)m-, -O-, or
but if V is -O- or
R³ and R⁴ must complete an aromatic ring;
W is -(CH₂)₂-, -CH=CH- or phenylene;
X is a single bond, -CH=CH-, -(CH₂)n-, or -O-(CH₂)n-; or X is branched alkylene or -O-branched alkylene wherein W is linked to Y through a chain n carbon atoms long;
Y is -CO₂H, -CO₂alkyl, -CO₂alkali metal, -CH₂OH, -CONHSO₂R⁵, -CONHR⁶, or -CH₂-5-tetrazolyl;
Z is O or NH;
R³ and R⁴ are each independently hydrogen or alkyl or R³ and R⁴ together complete a ring optionally substituted through a ring carbon with a halo, lower alkyl, phenyl, halo (lower alkyl), halophenyl, oxo or hydroxyl group; and the remaining symbols are as defined in the specification.
式中化合物具有血栓素受体拮抗剂活性
其中
V 是-(CH₂)m-、-O-或
但如果 V 是 -O- 或
R³ 和 R⁴ 必须是完整的芳香环;
W 是-(CH₂)₂-、-CH=CH-或亚苯基;
X 是单键、-CH=CH-、-(CH₂)n- 或-O-(CH₂)n-;或 X 是支链亚烷基或-O-支链亚烷基,其中 W 通过 n 个碳原子长的链与 Y 连接;
Y 是-CO₂H、-CO₂烷基、-CO₂碱金属、-CH₂OH、-CONHSO₂R⁵、-CONHR⁶或-CH₂-5-四唑基;
Z 是 O 或 NH;
R³ 和 R⁴ 各自独立地为氢或烷基,或 R³ 和 R⁴ 共同组成一个环,可通过环碳任选被卤代、低级烷基、苯基、卤代(低级烷基)、卤代苯基、氧代或羟基取代;其余符号如说明书中所定义。